Beam Therapeutics Inc.: insider trades · United States · SEC (Form 4)

About Beam Therapeutics Inc.

Beam Therapeutics Inc. is a U.S.-listed biotechnology company trading on NASDAQ in the United States, focused on precision genetic medicines built around base editing. The company was founded in January 2017 and began operations in July 2017. Its principal offices are in Cambridge, Massachusetts. Beam’s core thesis is that base editing can enable highly targeted DNA changes without introducing a double-strand break, which may offer a differentiated profile versus earlier gene-editing approaches. In strategic terms, Beam is working to build a fully integrated precision genetic medicine platform with the long-term ambition of delivering durable, potentially curative therapies for serious genetic diseases. Operationally, Beam’s pipeline is organized around two main franchises: hematology and genetic disease. Its lead program, BEAM-101, is being developed for sickle cell disease using an ex vivo autologous hematopoietic stem cell approach. The therapy is designed to raise fetal hemoglobin and reduce the pathological effects of sickle hemoglobin, supporting the company’s positioning around a potential one-time treatment with disease-modifying depth. In parallel, Beam is advancing BEAM-302 for alpha-1 antitrypsin deficiency (AATD), a liver-related genetic disorder where the company is pursuing direct correction of the underlying mutation. Beam has also announced a new liver-targeted program in phenylketonuria (PKU), broadening the platform beyond its initial hematology focus. From a competitive standpoint, Beam sits among the more prominent names in next-generation gene editing. The opportunity set is large, but so are the execution risks: clinical translation, regulatory review, manufacturing scale-up, and eventual commercialization all remain high-bar hurdles. A meaningful strategic advantage is Beam’s internal manufacturing capability, which can matter materially in cell and gene therapy, where process control and supply reliability are critical. The company has also historically used collaborations with larger biopharma partners to extend its reach and validate aspects of its platform. Recent milestones have been important. In 2025, the U.S. FDA granted RMAT designation to BEAM-101 for sickle cell disease, following orphan drug designation earlier in the year. Beam also reported that 30 patients had been dosed in the BEACON Phase 1/2 trial of BEAM-101, while management highlighted encouraging clinical updates for BEAM-302 in AATD. Overall, Beam remains a pre-commercial company, but one with several visible clinical catalysts and a platform narrative that continues to attract close attention from investors monitoring the U.S. NASDAQ biotech space.